Literature DB >> 25030650

Molecular and cellular basis of scleroderma.

Beate Eckes1, Pia Moinzadeh, Gerhard Sengle, Nico Hunzelmann, Thomas Krieg.   

Abstract

Systemic sclerosis (scleroderma) is a chronic inflammatory disease that leads to fibrosis of the skin and involved internal organs. No efficient therapy is currently available. This review summarizes recent progress made in basic as well as clinical science and concludes with a concept that therapy targeting fibrosis in scleroderma needs to take into account the global microenvironment in the skin with its diverse cellular players interacting with a complex extracellular matrix environment and matrix-associated growth factors.

Entities:  

Mesh:

Year:  2014        PMID: 25030650     DOI: 10.1007/s00109-014-1190-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  125 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype.

Authors:  D Kessler; S Dethlefsen; I Haase; M Plomann; F Hirche; T Krieg; B Eckes
Journal:  J Biol Chem       Date:  2001-07-23       Impact factor: 5.157

Review 3.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

4.  Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1.

Authors:  Teet Velling; Juha Risteli; Krister Wennerberg; Deane F Mosher; Staffan Johansson
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

5.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

6.  Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis.

Authors:  C M Artlett; J B Smith; S A Jimenez
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

Review 7.  Review: evidence that systemic sclerosis is a vascular disease.

Authors:  Marco Matucci-Cerinic; Bashar Kahaleh; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2013-08

8.  Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies.

Authors:  Carol Feghali-Bostwick; Thomas A Medsger; Timothy M Wright
Journal:  Arthritis Rheum       Date:  2003-07

9.  B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis.

Authors:  Jacob M van Laar
Journal:  Arthritis Res Ther       Date:  2010-04-22       Impact factor: 5.156

10.  Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.

Authors:  V Smith; J T Van Praet; B Vandooren; B Van der Cruyssen; J-M Naeyaert; S Decuman; D Elewaut; F De Keyser
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

View more
  19 in total

1.  Controlling the Balance of Fibroblast Proliferation and Differentiation: Impact of Thy-1.

Authors:  Manuela Schmidt; Danny Gutknecht; Jan C Simon; Jan-Niklas Schulz; Beate Eckes; Ulf Anderegg; Anja Saalbach
Journal:  J Invest Dermatol       Date:  2015-03-04       Impact factor: 8.551

2.  Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.

Authors:  Tetsuo Toyama; Agnieszka P Looney; Brendon M Baker; Lukasz Stawski; Paul Haines; Robert Simms; Aleksander D Szymaniak; Xaralabos Varelas; Maria Trojanowska
Journal:  J Invest Dermatol       Date:  2017-09-01       Impact factor: 8.551

3.  Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating Smad and TGF-β-activated kinase 1 (TAK1) pathways in mice.

Authors:  Wei-Qiang Tan; Qing-Qing Fang; Xiao Z Shen; Jorge F Giani; Tuantuan V Zhao; Peng Shi; Li-Yun Zhang; Zakir Khan; You Li; Liang Li; Ji-Hua Xu; Ellen A Bernstein; Kenneth E Bernstein
Journal:  Br J Pharmacol       Date:  2018-10-08       Impact factor: 8.739

Review 4.  Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

5.  Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF-β1 pathways.

Authors:  Qing-Qing Fang; Xiao-Feng Wang; Wan-Yi Zhao; Shi-Li Ding; Bang-Hui Shi; Ying Xia; Hu Yang; Li-Hong Wu; Cai-Yun Li; Wei-Qiang Tan
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

6.  Antioxidants and NOX1/NOX4 inhibition blocks TGFβ1-induced CCN2 and α-SMA expression in dermal and gingival fibroblasts.

Authors:  Hannah Murphy-Marshman; Katherine Quensel; Xu Shi-Wen; Rebecca Barnfield; Jacalyn Kelly; Alex Peidl; Richard J Stratton; Andrew Leask
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

Review 7.  The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy.

Authors:  Amaal E Abdulle; Gilles F H Diercks; Martin Feelisch; Douwe J Mulder; Harry van Goor
Journal:  Front Physiol       Date:  2018-08-24       Impact factor: 4.566

Review 8.  Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis.

Authors:  Pier Andrea Nicolosi; Enrico Tombetti; Norma Maugeri; Patrizia Rovere-Querini; Silvia Brunelli; Angelo A Manfredi
Journal:  Stem Cells Int       Date:  2016-03-16       Impact factor: 5.443

Review 9.  MicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic Sclerosis.

Authors:  Yisha Li; Jing Huang; Muyao Guo; Xiaoxia Zuo
Journal:  Genomics Proteomics Bioinformatics       Date:  2015-09-11       Impact factor: 7.691

Review 10.  Pathophysiological Mechanisms in Sclerosing Skin Diseases.

Authors:  Beate Eckes; Fang Wang; Pia Moinzadeh; Nicolas Hunzelmann; Thomas Krieg
Journal:  Front Med (Lausanne)       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.